Altos Labs vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Altos Labs is a longevity biotech company focused on cellular rejuvenation programming to reverse disease and extend healthspan; raised $3B at launch in 2022 backed by Jeff Bezos and Yuri Milner;
About
Altos Labs is a biotechnology company incorporated in 2021 and publicly launched in January 2022 with an extraordinary $3 billion Series A — the largest biotech launch funding round in history. The company is backed by Jeff Bezos and Yuri Milner, among others, and is headquartered in San Carlos, California, with research institutes in Cambridge, UK, and Japan. Altos Labs is focused on biological reprogramming and cellular rejuvenation — the scientific field exploring whether Yamanaka factors (a set of transcription factors that can reset a cell's epigenetic age) can be applied therapeutically to reverse disease progression and restore cellular function in aging tissues without causing cancer or loss of cell identity.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Altos Labs vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.